The results of a Phase III study have provided evidence that the drug apomorphine, first produced in 1865, could be effective in the management of advanced Parkinson’s disease. The study will be presented at the American Academy of Neurology’s 69th Annual Meeting in Boston (MA, USA), April 22–28, 2017.
Restricted Content / Members Only
You cannot view this content because It is available to members only. Please Login or Register to view this area.